Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept in Severe Scalp Alopecia Areata
NCT00167102Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Jul 2005
- Primary completion
- Feb 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Alefacept with Placebo (2 arms). Primary endpoints: Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values at 24 weeks and Number of Adverse Events at 24 weeks. Started Jul 2005; status: completed.
02
Drugs
alefacept
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT00167102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167102.